Vraylar Capsule, Gelatin Coated
Product Images NDC 61874-115

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Vraylar (NDC 61874-115). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Chemical Structure For Vraylar Is Cariprazine HCl, An Atypical Antipsychotic. The Chemical Name Is Trans-n-{4-[2-[4-(2,3 Dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-n’,n’-dimethylurea Hydrochloride; Its Empirical Formula Is C21h33cl3n4o And Its Molecular Weight Is 463.9 G/mol. (Vraylar 01)

Chemical structure of cariprazine hydrochloride, the active ingredient in Vraylar. The diagram shows atomic connectivity including nitrogen, oxygen, chlorine atoms, and a piperazine ring consistent with cariprazine's molecular structure.*

FDA Label Image

Figure 1. Plasma Concentration (mean ± Se)-time Profile During And Following12-weeks Of Treatment With Cariprazine 6 mg/daya (Vraylar 02)

A line graph showing plasma concentration (nM) over time (weeks) for multiple compounds related to Vraylar (cariprazine). The graph includes curves for total cariprazine (TOTAL CAR), desmethyl cariprazine (DDCAR), cariprazine (CAR), and didesmethyl cariprazine (DCAR), with error bars indicating variability at each time point.*

FDA Label Image

Figure 2 Change From Baseline In Panss Total Score By Weekly Visits (study 2) (Vraylar 03)

Line graph depicting change from baseline over six weeks comparing placebo, Vraylar 3 mg/day, and Vraylar 6 mg/day. The y-axis represents change from baseline, the x-axis represents weeks, showing greater decreases for Vraylar doses than placebo.*

FDA Label Image

Figure 3 Kaplan-meier Curves Of Cumulative Rate Of Relapse During The Double-blind Treatment Period (Vraylar 04)

A cumulative incidence plot comparing Cariprazine 3-9 mg and placebo over approximately 540 days of double-blind treatment. The y-axis represents cumulative incidence percentage, and the x-axis shows treatment duration in days. A green solid line represents Cariprazine 3-9 mg, and a blue dotted line indicates placebo. The chart includes risk and event count data below the x-axis for both groups at various time points.*

FDA Label Image

Figure 4 Change From Baseline In Ymrs Total Score By Study Visit (study 1) (Vraylar 05)

Packaging label for Vraylar (cariprazine) capsules, 1.5 mg per capsule, supplied in a carton containing 7 gelatin-coated capsules. The label includes the proprietary name, generic name, strength, and a prescriber warning to dispense a medication guide. Labeler is Allergan, Inc.*

FDA Label Image

Principal Display Panelndc 61874-115-17vraylar(cariprazine) Capsules1.5 mg Per Capsule7 Capsulesrx Only (Vraylar 06)

Packaging label for Vraylar (cariprazine) capsules, 1.5 mg per capsule, gelatin coated oral capsules. The label includes instructions for opening the child-resistant package and indicates a package size of 7 capsules. The labeler is Allergan, Inc. The label features the Vraylar brand name, drug strength, and a barcode.*

FDA Label Image

Principal Display Panelndc 61874-115-30vraylar(cariprazine) Capsules1.5 mg Per Capsule30 Capsulesrx Only (Vraylar 07)

Vraylar 1.5 mg capsule label displaying the proprietary name and generic name cariprazine. The gelatin-coated oral capsules are packaged in a container with 30 capsules. The label includes dosage strength, barcode, NDC number 61874-115-30, storage instructions, and manufacturer Allergan, Inc. It also contains a reminder for prescribers to provide the medication guide to patients.*

FDA Label Image

Principal Display Panelndc 61874-115-90vraylar(cariprazine) Capsules1.5 mg Per Capsule90 Capsulesrx Only (Vraylar 08)

Vraylar (cariprazine) capsules 1.5 mg strength packaging label. The label shows a teal and white carton with brand name Vraylar prominently displayed. Each capsule contains 1.5 mg cariprazine base. The package is labeled for prescription use only and contains 20 capsules (2 blister cards of 10 count each). The labeler is Allergan, Inc., and storage instructions are included.*

FDA Label Image

Principal Display Panelndc 61874-115-20vraylar(cariprazine) Capsules1.5 mg Per Capsule20 Capsules (2x10-count Blister Cards)rx Only (Vraylar 09)

Vraylar (cariprazine) capsules packaging label showing a combination of one 1.5 mg capsule and six 3 mg capsules. The label includes the proprietary name Vraylar, generic name cariprazine, product form as capsules, and the labeler Allergan, Inc. The package includes 7 capsules in total and a note directing prescribers to dispense a medication guide to each patient.*

FDA Label Image

Principal Display Panelndc 61874-170-08vraylar(cariprazine) Capsulesone 1.5 mg Capsule And Six 3 mg Capsules7 Capsulesrx Only (Vraylar 0a)

Vraylar 3 mg gelatin coated capsules label showing the product name, active ingredient cariprazine, strength of 3 mg per capsule, and package count of 30 capsules. The label includes storage instructions, prescription-only status, manufacturer Allergan, Inc., and barcode details.*

FDA Label Image

Principal Display Panelndc 61874-130-30vraylar(cariprazine) Capsules3 mg Per Capsule30 Capsulesrx Only (Vraylar 0b)

Vraylar 3 mg per capsule gelatin coated oral capsules packaging label by Allergan, Inc. The label includes the proprietary name Vraylar, generic name cariprazine, strength 3 mg per capsule, and quantity 20 capsules (2 blister cards). It contains storage instructions, usage caution to keep out of reach of children, and mentions Rx only. The NDC code is 61874-130-20.*

FDA Label Image

Principal Display Panelndc 61874-130-90vraylar(cariprazine) Capsules3 mg Per Capsule90 Capsulesrx Only (Vraylar 0c)

Label for Vraylar capsules, containing cariprazine at 4.5 mg per capsule in gelatin-coated oral form. The label includes dosage instructions, manufacturer Allergan, Inc., package size of 30 capsules, storage conditions, and regulatory information. The product is prescription-only with an NDC of 61874-145-30.*

FDA Label Image

Principal Display Panelndc 61874-130-20vraylar(cariprazine) Capsules3 mg Per Capsule20 Capsules (2x10-count Blister Cards)rx Only (Vraylar 0d)

Vraylar 6 mg per capsule gelatin coated capsules label, containing cariprazine as the active ingredient. The label shows that the package contains 30 capsules, with instructions for prescribers to dispense a medication guide. It includes storage information and distributor details, Allergan USA, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.